• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    6/26/23 9:12:38 AM ET
    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    Gainers

    • MoonLake (NASDAQ:MLTX) shares increased by 80.5% to $46.71 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
    • INVO Bioscience (NASDAQ:INVO) shares rose 50.06% to $0.25. The company's market cap stands at $3.4 million.
    • Femasys (NASDAQ:FEMY) stock rose 36.63% to $0.84. The company's market cap stands at $11.0 million.
    • Benitec Biopharma (NASDAQ:BNTC) shares increased by 35.77% to $0.27. The market value of their outstanding shares is at $7.5 million.
    • SQZ Biotechnologies (NYSE:SQZ) shares moved upwards by 30.29% to $0.52. The company's market cap stands at $15.3 million.
    • CollPlant Biotechnologies (NASDAQ:CLGN) shares increased by 19.19% to $9.5. The market value of their outstanding shares is at $108.1 million.

    Losers

    • Avalo Therapeutics (NASDAQ:AVTX) shares fell 85.2% to $0.66 during Monday's pre-market session. The company's market cap stands at $8.6 million.
    • FibroGen (NASDAQ:FGEN) shares declined by 78.2% to $3.5. The market value of their outstanding shares is at $341.5 million.
    • Surgalign Holdings (NASDAQ:SRGA) stock decreased by 26.64% to $0.21. The company's market cap stands at $1.8 million.
    • Nutriband (NASDAQ:NTRB) stock declined by 16.16% to $1.92. The company's market cap stands at $15.0 million.
    • SCWorx (NASDAQ:WORX) stock decreased by 14.31% to $0.45. The company's market cap stands at $5.8 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) stock declined by 13.15% to $1.85. The market value of their outstanding shares is at $14.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $BNTC
    $BPTH
    $CLGN

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    MoonLake Immunotherapeutics
    $MLTX
    1/15/2026$10.00Neutral → Sell
    Goldman
    MoonLake Immunotherapeutics
    $MLTX
    1/9/2026$24.00Neutral → Buy
    BTIG Research
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    MoonLake Immunotherapeutics
    $MLTX
    11/3/2025$30.00Neutral → Buy
    H.C. Wainwright
    MoonLake Immunotherapeutics
    $MLTX
    10/2/2025Buy → Neutral
    H.C. Wainwright
    MoonLake Immunotherapeutics
    $MLTX
    10/1/2025$7.00Buy → Neutral
    Goldman
    More analyst ratings

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00

    1/15/26 8:33:55 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics upgraded by BTIG Research with a new price target

    BTIG Research upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    3/6/26 10:05:20 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by CollPlant Biotechnologies Ltd

    6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

    2/26/26 9:01:35 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    SEC Form 1-Z filed by Bio-Path Holdings Inc.

    1-Z - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    2/25/26 4:44:21 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Varki Paul

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:24:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Strategy Officer Riley Jennifer

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:32 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:06 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

    -- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to advance the study based on positive clinical data generated in its

    3/10/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

    HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment l

    3/10/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

    - Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia - BB-301 is the only clinical-stage th

    3/9/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AVTX
    $BNTC
    $BPTH
    $CLGN
    Financials

    Live finance-specific insights

    View All

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutriband CEO Publishes Letter to Shareholders

    ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way. This goal

    12/31/25 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

    REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhColla

    11/18/25 7:00:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care